Single-center, Single-arm Phase I Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/recurrent Advanced Solid Tumors
Latest Information Update: 20 Feb 2025
At a glance
- Drugs GT-201 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Cervical cancer; Multiple myeloma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GRIT Biotechnology
Most Recent Events
- 06 Jun 2023 Results of dose escalation study (n=4) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 30 Jun 2022 New trial record